Hot Investor Mandate: VC Firm Invests in North America-Based Deeptech Companies, Including Healthcare Companies Addressing the Aging and Chronic Diseases Market

16 Nov

A venture capital firm founded in 2016 with a primary office in the US will soon be investing from a third fund, dedicated towards seed-stage companies that solve the most critical problems of today. The typical check size is around $1M USD and the firm expects to invest in 4-6 companies in the next year. The firm invests globally with a focus on North America.

The firm is mainly focused on deep tech opportunities related to prevalent industrial, agriculture, climate, and healthcare issues. Within healthcare, the firm is primarily interested in scalable technologies that assist the aging population and chronic diseases and address rising healthcare costs. The firm is open to all modalities within the diagnostics, medical devices, and biomanufacturing spaces, but does not invest in therapeutics. Though opportunistic, the firm looks for technology in development phases that can seamlessly be integrated into workflows and meet the existing market demand. The firm is open to all indications related to the aging population and chronic disease, including renal health, heart disease, and oncology.

The firm is looking for coachable, open-minded, and growth-centered management teams. The firm will typically lead and require board seat to work closely with companies. However, co-leading and syndicate investments are also feasible.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Leave a comment